Page 2 - Clinical Development Program News Today

TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 -- Regeneron...

Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today

– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision – – Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three...

– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apart –– Detailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, a...

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis If approved,...